CAS: 130641-38-2; 2-[(1-Benzylindazol-3-yl)Methoxy]-2-Methylpropanoic Acid
- 英文名称2-[(1-Benzylindazol-3-yl)Methoxy]-2-Methylpropanoic Acid
- 中文名称宾达利
- IUPAC名称2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid
- 其它别名2-[(1-Benzyl-1H-indazol-3-yl)methoxy]-2-methylpropanoicacid; 2-[(1-Benzyl-1H-indazol-3-yl)methoxy]-2-methylpropionic acid; Bindarit
- CAS编号130641-38-2
- MFCD编号:MFCD00866723
- FDA UNII编号:JQ11LH711M
- 分子式:C19H20N2O3分子量:324.37
- 产品CID: 464752
- 产品分类生物化工 → 生化试剂 → 激动剂抑制剂
物理性质
MSDS等安全信息
上下游产品
CAS号205643-28-3 1-苄基-3-碘-1H-吲唑 | CAS号100-39-0 溴化苄 | CAS号40598-94-5 3-溴吲唑 | CAS号131427-21-9 1-苄基-3-羟基甲基-1H-吲唑 | CAS号1186509-61-4 1-benzyl-1H-ind... | CAS号29985-03-3 1-Benzyl-3-brom...合成工艺路线路线简述
📜Ethyl 2-((1-Benzyl-1H-Indazol-3-yl)Methoxy)-2-Methylpropanoate 以85的收率获得宾达利
参考文献: Process For The Preparation Of 1-Benzyl-3-Hydr0Xymethyl-1H-Indaz0Le And Its Derivatives And Required Magnesium Intermediates[fr] Procédé Pour La Préparation De 1-Benzyl-3-Hydroxyméthyl-1H-Indazole Et De Ses Dérivés Et Intermédiaires Au Magnésium Correspondants
标题: Process For The Preparation Of 1-Benzyl-3-Hydr0Xymethyl-1H-Indaz0Le And Its Derivatives And Required Magnesium Intermediates[fr] Procédé Pour La Préparation De 1-Benzyl-3-Hydroxyméthyl-1H-Indazole Et De Ses Dérivés Et Intermédiaires Au Magnésium Correspondants
摘要:本发明涉及一种制备1-苄基-3-羟甲基-1H-吲唑(化学式(II))的过程,用于随后制备1-苄基-3-羟甲基-1H-吲唑(化学式(i))的过程.
海关参考信息
- 2902300000-甲苯
2905122000-异丙醇
2905143000-叔丁醇
2905310000-1,2-乙二醇 - 💡 提示：海关信息按照顺序优先匹配，如需确认的海关信息，请参考相关资料。
- 详情请参考：📖 海关编码查询和海关进出口税则
专利信息
专利号:US-12122751-B2
优先权日:2019-06-25
标 题 :Processes of making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives
发明人：JIAO XIANGDONG; KHUMTAVEEPORN KANJAI
权利人:TRANSLATUM MEDICUS INC
摘要:The invention in this disclosure is related to the processes of making Bindarit or derivatives thereof. Specifically, the present invention provides, in part, new processes for making 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid and its derivatives. By way of non-limiting example, synthesis and purification processes of 2-((1-benzyl-1H-indazol-3-yl)methoxy)-2-methylpropanoic acid are provided by the invention in this disclosure.
专利号:US-2014315720-A1
优先权日:2012-10-24
标 题 :Polysaccharide ester microspheres and methods and articles relating thereto
发明人：FALLON DENIS G; GARRETT THOMAS S; KIZER LAWTON E; ZAZZARA KAREN L; COMBS MICHAEL T; JOHNSON RICHARD K; DEHART GARY
权利人:CELANESE ACETATE LLC
摘要:A method for producing a polysaccharide ester microsphere may include forming a polysaccharide ester product from a polysaccharide synthesis, wherein the polysaccharide ester product comprises a polysaccharide ester and a solvent; diluting the polysaccharide ester product, thereby yielding a polysaccharide ester dope; and forming a plurality of polysaccharide ester microspheres from the polysaccharide ester dope. Suitable polysaccharides may include, but are not limited to, starch, cellulose, hemicellulose, algenates, chitosan, and any combination thereof. Esters thereof may be organic esters (e.g., acetate and the like), inorganic esters (e.g., sulfonates and the like), or combinations thereof. Further, the solids conent of the polysaccharide ester dope, in some instances, may be greater than about 16 wt %.
专利号:CN-106316958-A
优先权日:2015-06-19
标 题:A kind of preparation method of indazole and its application in drug synthesis
专利号:CN-106316958-B
优先权日:2015-06-19
标 题 :A kind of preparation method of indazole and its application in drug synthesis
供应商参考报价(招募中)
品牌试剂参考报价(招募中)
📌 第三方产品分析报告
主要参考文献
1: Colombo A, Basavarajaiah S, Limbruno U, Picchi A, Lettieri C, Valgimigli M, Sciahbasi A, Prati F, Calabresi M, Pierucci D, Guglielmotti A. A double-blind randomised study to evaluate the efficacy and safety of bindarit in preventing coronary stent restenosis. EuroIntervention. 2015 Dec 23;11(8). pii: 20140918-01. doi: 10.4244/EIJY15M12_03. [Epub ahead of print] doi: 10.1128/JVI.02114-15.
3: Zoja C, Corna D, Locatelli M, Rottoli D, Pezzotta A, Morigi M, Zanchi C, Buelli S, Guglielmotti A, Perico N, Remuzzi A, Remuzzi G. Effects of MCP-1 inhibition by bindarit therapy in a rat model of polycystic kidney disease. Nephron. 2015;129(1):52-61. doi: 10.1159/000369149. Epub 2014 Dec 17. doi: 10.1128/JVI.02034-14. Epub 2014 Oct 22. Erratum in: J Virol. 2015 Dec 1;89(23):12232.
5: Steiner JL, Davis JM, McClellan JL, Guglielmotti A, Murphy EA. Effects of the MCP-1 synthesis inhibitor bindarit on tumorigenesis and inflammatory markers in the C3(1)/SV40Tag mouse model of breast cancer. Cytokine. 2014 Mar;66(1):60-8. doi: 10.1016/j.cyto.2013.12.011. Epub 2014 Jan 20.
合成参考文献
参考文献:10.2165/00128072-200204040-00004|10.2165/00148581-200204040-00004
摘要:Carreño L, López-Longo FJ, González CM, Monteagudo I. Treatment options for juvenile-onset systemic lupus erythematosus. Paediatr Drugs. 2002;4(4):241–56. doi: 10.2165/00128072-200204040-00004.
参考文献:10.1007/s12307-012-0126-7
摘要:Umansky V, Sevko A. Tumor Microenvironment and Myeloid-Derived Suppressor Cells. Cancer Microenvironment. 2012 Dec 16;6(2):169–77. doi: 10.1007/s12307-012-0126-7.
参考文献:10.1007/s11892-015-0685-3
摘要:Khan SS, Quaggin SE. Therapies on the Horizon for Diabetic Kidney Disease. Current Diabetes Reports. 2015 Oct 12;15(12):111. doi: 10.1007/s11892-015-0685-3.
参考文献:10.1007/bf02979157
摘要:Saso L, Valentini G, Mattei E, Panzironi C, Casini ML, Grippa E, Silvestrini B. Stabilization of rat serum proteins following oral administration of fish oil. Archives of Pharmacal Research. 1999 Oct;22(5):485–90. doi: 10.1007/bf02979157.
📝 需求与反馈
尽可能描述清楚需求与问题信息
